Expression of genes for thioredoxin 1 and thioredoxin 2 in multidrug resistance ovarian carcinoma cells SKVLB

Bulletin of Experimental Biology and Medicine

Volumn 144, Issue 3, 2007, Pages 301-303

  Kalinina, E V ^b   Chernov, N N ^c   Saprin, A N ^a   Kotova, Ya N ^a   Gavrilova, Yu A ^a   Chermnykh, N S ^a   Shcherbak, N P ^a  

^a CENTER FOR THEORETICAL PROBLEMS OF PHYSICOCHEMICAL PHARMACOLOGY   (Russian Federation)

^b Institute of Cytochemistry and Molecular Pharmacology   (Russian Federation)

^c PEOPLES FRIENDSHIP UNIVERSITY OF RUSSIA   (Russian Federation)

Author keywords

Doxorubicin; Drug resistance; Thioredoxin

Indexed keywords

DOXORUBICIN; THIOREDOXIN; THIOREDOXIN 1; THIOREDOXIN 2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; MULTIDRUG RESISTANCE; OVARY CARCINOMA; PHARMACOGENETICS;

CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; ISOENZYMES; OVARIAN NEOPLASMS; THIOREDOXINS;

EID: 37749044953     PISSN: 00074888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10517-007-0316-3     Document Type: Article

References (14)

1. G. Bradley, M. Naik, and V. Ling, Cancer Res., 49, No. 10, 2790-2796 (1989).
2. K. C. Das and C. K. Das, Biochem. Biophys. Res. Commun., 277, No. 2, 443-447 (2000).
3. D. Dreher and A. F. Junod, Eur. J. Cancer, 32A, No. 1, 30-38 (1996).
4. T. M. Grogan, C. Fenoglio-Prieser, R. Zeheb, et al., Hum. Pathol., 31, No. 4, 475-481 (2000).
5. S. Hashimoto, K. Matsumoto, Y. Gon, et al., Biochem. Biophys. Res. Commun., 258, No. 2, 443-447 (1999).
6. K. Hirota, M. Murata, Y. Sachi, et al., J. Biol. Chem., 274, No. 39, 27,891-27,897 (1999).
7. M. Luthman and A. Horlmgren, Biochemistry, 21, No. 26, 6628-6633 (1982).
8. H. Nakamura, K. Nakamura, and J. Yodoi, Annu. Rev. Immunol., 15, 351-369 (1997).
9. J. R. Pedrajas, E. Kosmidou, A. Miranda-Vizuete, et al., J. Biol. Chem., 274, No. 10, 6366-6373 (1999).
10. J. R. Pedrajas, A. Miranda-Vizuete, N. Javanmardy, et al., Ibid., 275, No. 21, 16,295-16,301 (2000).
11. G. Powis, J. R. Gasdaska, and A. Baker, Adv. Pharmacol., 38, 329-359 (1997).
12. G. Powis and W. R. Montfort, Annu. Rev. Pharmacol. Toxicol., 41, 261-295 (2001).
13. P. G. Reddy, D. K. Bhuyan, and K. C. Bhuyan, Biochem. Biophys. Res. Commun., 265, No. 2, 345-349 (1999).
14. T. Sasada, S. Iwata, N. Sato, et al., J. Clin. Invest., 97, No. 10, 2268-2276 (1996).